CG Power and Industrial
BSE SENSEX
31,028
Bloomberg
Equity Shares (m)
M.Cap.(INRb)/(USDb)
52-Week Range (INR)
1, 6, 12 Rel. Per (%)
Avg Val, INRm
Free float (%)
S&P CNX
9,595
CRG IN
627
58.9 / 0.9
97 / 56
14/9/36
348
65.6
27 May 2017
4QFY17 Results Update | Sector: Capital Goods
CMP: INR93
TP: INR65(-31%)
Sell
Standalone performance ahead of estimates
Standalone operating performance exceeds expectations:
Sales rose 7% YoY to
INR12.8b (est. of INR11.6b), driven by 16.9% growth in Industrial segment, while
Power segment sales were flat YoY. EBIDTA margin at 6.3% was ahead of our
estimate of 5.8%. Adj. PAT of INR0.5b exceeded our estimate of INR0.3b, led by
higher-than-estimated other income (INR350m v/s est. of INR273m) and tax
write-back of INR101m.
Consol. performance includes Indonesian subsidiary from 4QFY17:
Consol.
revenue (incl. Indonesian subsidiary) declined 8% YoY to INR17.1b in 4QFY17
due to a decline in Power Systems (-17% YoY). Industrial segment grew 12%
YoY. EBIDTA declined 24% YoY to INR1.2b, with the margin contracting 150bp
YoY to 6.9%. Adj. PAT of INR376m was down 64% YoY. An impairment loss of
INR3b was booked post the sale of ZIV Systems in 4QFY17, while the balance is
accounted for by overseas Power T&D subs.
Sale of ZIV concludes; divestment of power business in US in final stages:
CRG
concluded the ZIV sale in March 2017 for INR7b, and is in advanced stages of
sale of its US-based power systems business. It expects the deal to conclude by
June 2017.
Maintain Sell; revise TP to INR65:
We raise our estimates for FY17/FY18 by
28%/9% to factor in: a) sale of ZIV Systems, b) Indonesian subsidiary which is
reclassified as continuing operations, c) lower losses from overseas T&D
businesses (INR1.2b/annum). We would revisit our numbers once we get more
clarity on sale/closure of overseas T&D businesses. We roll over to FY19, but
maintain
Sell
with a TP of INR65 (25x FY19E EPS, 20% premium to 5-year
average of 20x). Key upside risks to our rating are: a) sale of overseas T&D
business and b) a sharp fall in competition in domestic T&D segment.
Financials & Valuations (INR b)
Y/E Mar
2017 2018E 2019E
Net Sales
61.2
61.5
68.1
EBITDA
4.7
4.7
5.1
Adj PAT
-4.2
1.4
1.6
EPS(INR)
2.9
2.2
2.5
EPS Gr. (%)
-18.6 -25.4
15.6
BV/Sh. (INR)
65.6
67.6
69.9
RoE (%)
4.2
6.1
6.4
RoCE (%)
6.8
7.6
6.8
P/E (x)
31.9
42.8
37.0
P/BV (x)
1.4
1.4
1.3
Estimate change
TP change
Rating change
Investors are advised to refer through important disclosures made at the last page of the Research Report.
Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.
Ankur Sharma
(Ankur.VSharma@MotilalOswal.com); +91 22 6129 1556
Amit Shah
(Amit.Shah@MotilalOswal.com); +91 22 6129 1543